Epigenetic regulation of inflammation in periodontitis : cellular mechanisms and therapeutic potential by unknown
Jurdziński et al. Clin Epigenet          (2020) 12:186  
https://doi.org/10.1186/s13148-020-00982-7
REVIEW
Epigenetic regulation of inflammation 
in periodontitis: cellular mechanisms 
and therapeutic potential
Krzysztof T. Jurdziński1, Jan Potempa1,2 and Aleksander M. Grabiec1* 
Abstract 
Epigenetic mechanisms, namely DNA and histone modifications, are critical regulators of immunity and inflamma-
tion which have emerged as potential targets for immunomodulating therapies. The prevalence and significant 
morbidity of periodontitis, in combination with accumulating evidence that genetic, environmental and lifestyle 
factors cannot fully explain the susceptibility of individuals to disease development, have driven interest in epigenetic 
regulation as an important factor in periodontitis pathogenesis. Aberrant promoter methylation profiles of genes 
involved in inflammatory activation, including TLR2, PTGS2, IFNG, IL6, IL8, and TNF, have been observed in the gingival 
tissue, peripheral blood or buccal mucosa from patients with periodontitis, correlating with changes in expression 
and disease severity. The expression of enzymes that regulate histone acetylation, in particular histone deacetylases 
(HDACs), is also dysregulated in periodontitis-affected gingival tissue. Infection of gingival epithelial cells, gingival 
fibroblasts and periodontal ligament cells with the oral pathogens Porphyromonas gingivalis or Treponema denticola 
induces alterations in expression and activity of chromatin-modifying enzymes, as well as site-specific and global 
changes in DNA methylation profiles and in histone acetylation and methylation marks. These epigenetic changes are 
associated with excessive production of inflammatory cytokines, chemokines, and matrix-degrading enzymes that 
can be suppressed by small molecule inhibitors of HDACs (HDACi) or DNA methyltransferases. HDACi and inhibitors 
of bromodomain-containing BET proteins ameliorate inflammation, osteoclastogenesis, and alveolar bone resorption 
in animal models of periodontitis, suggesting their clinical potential as host modulation therapeutic agents. However, 
broader application of epigenomic methods will be required to create a comprehensive map of epigenetic changes 
in periodontitis. The integration of functional studies with global analyses of the epigenetic landscape will provide 
critical information on the therapeutic and diagnostic potential of epigenetics in periodontal disease.
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Introduction
Periodontitis is an inflammatory disease initiated and 
sustained by oral microbial biofilm (dental plaque) [1]. 
While keystone pathogens, such as Porphyromonas gin-
givalis, Tannerella forsythia, and Treponema denticola, 
play crucial roles in disease development and progres-
sion, it is now commonly accepted that periodontitis 
is caused by dysbiosis rather than specific periodontal 
pathogen(s) [2]. In periodontitis-affected gingival tis-
sue, infiltrating immune cells and resident gingival 
cells, in particular gingival epithelial cells (GECs) and 
fibroblasts, produce excessive amounts of cytokines, 
chemokines, and matrix-degrading enzymes in a futile 
attempt to eliminate periodontal pathogens. Instead, 
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chronic production of these mediators drives inflam-
matory tissue breakdown, which provides nutrients 
for inflammophilic bacteria. As a consequence, non-
resolving inflammation both sustains dysbiotic micro-
biota and is the main cause of periodontitis-related 
tissue damage [3]. The rapidly growing body of evi-
dence indicates that apart from the inevitable tooth 
loss, untreated periodontitis is strongly associated with 
increased risk of developing a number of systemic dis-
eases, such as rheumatoid arthritis [4], Alzheimer’s dis-
ease [5], cardiovascular disease, diabetes, and cancer 
[6].
Historically, the most common forms of non-
necrotizing periodontitis have been divided into two 
pathophysiologically distinct forms of disease: chronic 
periodontitis, characterized by late-onset and slow 
progression, and less common aggressive periodonti-
tis, characterized by early-onset and rapid progression 
[7]. While aggressive periodontitis is strongly associ-
ated with genetic risk factors, the importance of the 
genetic component is much less evident in patients 
with chronic disease [8]. Although a new classification 
system for periodontitis has been recently developed 
[7], a vast majority of the epigenetic studies discussed 
in this review have been conducted on patient cohorts 
assembled before the introduction of these classifica-
tion criteria and used the distinction between chronic 
and aggressive disease. Here, we will discuss studies 
performed on patients with the chronic form of the 
disease, referring to them as periodontitis patients, as 
well as reports describing groups of young individuals 
with above-average speed of disease progression, call-
ing them aggressive periodontitis patients.
Due to the significant morbidity of periodontitis and 
associated diseases, there is a pressing need for develop-
ing novel therapeutic approaches to support the currently 
used strategies that focus on limiting the bacterial chal-
lenge (scaling and root planning or root surface debride-
ment). Because of that, there is a growing interest in a 
new therapeutic approach, called host modulation ther-
apy. This strategy is based on the idea that conventional 
periodontal treatment is supported by therapeutic agents 
that ameliorate destructive consequences of the host 
inflammatory response [1]. The emergence of this con-
cept coincided with the identification of essential roles of 
epigenetic mechanisms in immunity and inflammation 
and the anti-inflammatory potential of epigenetic drugs 
[9, 10]. This, in combination with evidence that genetic, 
environmental, and lifestyle factors cannot fully explain 
the susceptibility of individuals to disease development 
[11], has driven substantial interest in epigenetic regula-
tion as an important factor in periodontitis pathogenesis 
and a potential target for host modulation therapy.
Epigenetic mechanisms
The meaning of the term “epigenetics” varies across sci-
entific literature [12]. We will use this term in accordance 
with one of the unifying definitions, proposed by Bird: 
“the structural adaptation of chromosomal regions so as 
to register, signal, or perpetuate altered activity states,” 
[13] focusing on potentially heritable changes not involv-
ing alterations in DNA sequences [14]. Among these 
changes, DNA methylation and posttranslational modi-
fications (PTMs) of histones are the best characterized.
Methylation of cytosine is the most common modifica-
tion of DNA that occurs at CpG dinucleotides (cytosine 
followed by guanine). It typically causes chromatin con-
densation and disruption of interactions between DNA 
and transcription factors, which are associated with tran-
scriptional repression [15]. In addition to 5-methylcy-
tosine (5mC) residues, stable oxidized 5mC derivatives, 
such as 5-hydroxymethylcytosine (5hmC), are also com-
monly found throughout the genomic DNA. They are 
intermediates of DNA demethylation [16] that play inde-
pendent roles in functional chromatin organization [17]. 
DNA methylation marks are established, recognized, and 
deleted in a site-specific manner. Cytosine residues are 
methylated by DNA methyltransferases (DNMTs) and 
can undergo passive or active demethylation (Fig.  1a). 
DNMT1 in a complex with UHRF1 (ubiquitin like with 
PHD and ring finger domains 1) is responsible for con-
servation of CpG methylation after replication, whereas 
DNMT3a or DNMT3b in a complex with DNMT3L 
catalyze de novo methylation [15]. Both passive and 
active demethylation can involve oxidation of 5mC and 
its oxidized derivatives by TET (ten-eleven transloca-
tion) enzymes [16]. Active demethylation occurs through 
excision of 5-formylcytosine (5fC) or 5-carboxylcytosine 
(5caC) by thymine DNA glycosylase (TDG) and base-
excision repair (BER) [16]. In contrast, DNA undergoes 
passive demethylation in the course of DNA replica-
tion when DNMT1 is lacking or inhibited, or when the 
DNMT1:UHRF1 complex does not recognize the CpG 
site to be methylated as a result of 5mC oxidation [16].
Histones undergo a plethora of different PTMs, includ-
ing acetylation, methylation, phosphorylation, citrul-
lination, and ubiquitylation. They have various, often 
context-dependent effects on transcriptional activity and 
chromatin structure [15]. As it was unclear whether his-
tone PTMs are heritable, their status as epigenetic marks 
has been elusive. Still, recent reports provided clear 
evidence that some of these modifications are indeed 
mitotically stable in a locus-specific manner and this 
inheritance is biologically relevant [18, 19].
Amongst histone PTMs, acetylation is the best 
characterized in terms of mechanisms of regula-
tion and effects on transcription (Fig.  1b). Histone 
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acetyltransferases (HATs) acetylate lysine residues on 
histones while histone deacetylases (HDACs) remove 
acetyl groups [15]. Histone acetylation is strongly asso-
ciated with increased transcriptional activity, though 
distinct acetylation sites are involved in this process at 
different levels. Acetylation of lysines on H3 globular 
domains (in particular histone 3 lysine 56 [H3K56]) and 
H4K16 disrupt electrostatic interactions within and 
between the nucleosomes, promoting relaxation of the 
chromatin structure [20]. Acetylated lysines on H3 and 
H4 tails act as binding sites for specific bromodomain-
containing reader proteins, such as bromodomain and 
extra-terminal (BET) proteins, which regulate tran-
scription-related processes [21]. However, recent evi-
dence indicates that the interplay between acetylation 
and deacetylation in transcriptional regulation is more 
complex. Genome-wide mapping of HAT and HDACs 
revealed their unique functions at active and inactive 
genes, demonstrating that dynamic cycles of acetyla-
tion and deacetylation poise inactive genes for future 
activation [22]. Importantly, despite its essential role in 
transcriptional activation, histone acetylation alone is 
not sufficient for the induction of gene expression. This 
is exemplified by studies of HDAC inhibitors (HDACi). 
Although these compounds induce global histone 
hyperacetylation, they affect the expression of a rela-
tively small proportion of the transcribed genes, many 
of which are downregulated [23]. Similarly, lysine meth-
ylation, which is established by histone methyltrans-
ferases (HMTs) and removed by histone demethylases, 
affects chromatin structure and gene expression in a 
context-dependent manner [15]. For example, trimeth-
ylation marks at H3K27 and H3K9 are associated with 
repressed genes, whereas H3K4Me3 and H3K36Me3 
have been linked to transcriptional activation [24].
It should be noted that regulation of gene expression by 
non-coding RNAs, in particular by micro-RNAs, is clas-
sified as an epigenetic mechanism by some researchers. 
However, the contributions of non-coding RNAs to peri-
odontitis pathogenesis have been reviewed elsewhere [25, 
26] and will not be covered in this review. Similarly, the 
involvement of epigenetic regulation in periodontal dis-
ease has been thoroughly reviewed in the context of bone 
metabolism [27] and potential links with oncogenesis 
[28], so we will not discuss these aspects extensively here. 
In this review, we will focus predominantly on molecular 
Fig. 1 Schematic representation of the biochemical processes involved in DNA methylation and histone acetylation. a Unmethylated cytosine 
at the CpG site can be methylated de novo by DNMT3A or DNMT3B in complex with DNMT3L, the latter lacking methyltransferase activity. The 
DNMT1:UHRF1 complex is responsible for the conservation of the CpG methylation pattern on the complementary DNA strand after replication. 
TET enzymes catalyze the formation of oxidized 5mC derivatives, which are no longer recognized by the DNMT1:UHRF1 complex (passive 
demethylation). Additionally, 5fC and 5caC can be recognized and excised by TDG, leading to replacement with unmodified cytosine through BER 
(active demethylation). b N-terminal lysine residues on histone tails are acetylated by HATs, which leads to neutralization of their positive charge, 
relaxation of chromatin structure, and increased transcriptional accessibility of gene promoters. Bromodomain-containing proteins recognize 
specific acetyl-lysine containing sequences within the histone, promoting the formation of acetylation-dependent transcriptional complexes. 
Acetylated lysine residues can be deacetylated by HDACs. BER base-excision repair, DNMT DNA methyltransferase, HAT histone acetyltransferase, 
HDAC histone deacetylase, TET ten-eleven translocation, TDG thymine DNA glycosylase, UHRF1 Ubiquitin-like, containing PHD and RING finger 
domains-1
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and cellular processes affected by epigenetic mechanisms 
and their clinical implications.
Posttranslational histone modifications 
and chromatin‑modifying enzymes in periodontitis
Alterations in expression and function 
of chromatin‑modifying enzymes
In many chronic inflammatory diseases, alterations in 
expression and function of proteins that regulate post-
translational histone modifications are associated with 
pathology. Similarly, several bacterial pathogens manipu-
late histone acetylation in host cells to facilitate survival 
and evade the immune response [23]. Not surprisingly, 
changes in the expression patterns of proteins involved 
in chromatin remodeling have been identified in the 
inflamed gingival tissue and cells of the periodontium 
exposed to oral pathogens. Global HDAC expression pro-
filing in the gingival tissue from patients with periodonti-
tis and healthy controls produced conflicting data. Ateia 
et al. [29] reported reduced expression of several classes 
of chromatin-modifying enzymes, including class II 
HDACs in periodontitis-affected gingival tissue, though 
the differences were not verified at the protein level. Con-
versely, an independent study identified elevated tran-
script levels of several HDAC family members, including 
HDAC1, HDAC5, HDAC8, and HDAC9, in periodontitis 
patients compared to healthy individuals, though only 
the increased HDAC1 expression was confirmed at the 
protein level in immunohistochemical studies of the gin-
gival tissue [30]. Due to the limited sample sizes and the 
lack of detailed clinical characteristics of the analyzed 
patients, it is difficult to resolve the apparent discrepan-
cies between these studies. Previous evidence from other 
pathologies, in particular rheumatoid arthritis (RA), sug-
gests the importance of conducting more extensive anal-
yses of the equilibrium between HAT and HDAC activity, 
global and loci-specific histone acetylation as well as rela-
tionships with clinical and inflammatory disease parame-
ters [31, 32]. In this regard, it is noteworthy that elevated 
HDAC1 expression in the gingival tissue was associated 
with cells expressing tumor necrosis factor (TNF) [30]. 
Similar positive correlations between expression of TNF 
and HDAC1, as well as other class I HDACs, have been 
reported in the synovial tissue from RA patients [33, 34]. 
This observation suggests that increased levels of HDAC1 
in periodontitis may be related to the ongoing inflamma-
tory process rather than interaction with oral bacteria.
Studies of cells isolated from periodontal tissues 
revealed that HDAC expression is dynamically regulated 
by oral pathogens. Reduced expression of HDAC1 and 
HDAC2 was observed in GECs upon infection with P. 
gingivalis [35], whereas T. denticola challenge downreg-
ulated transcript levels of several class II HDAC family 
members, including HDAC4, HDAC6, and HDAC10 
in periodontal ligament (PDL) cells [29]. The reported 
downregulation of HDACs by oral pathogens favors his-
tone hyperacetylation and, indeed, oral pathogens and 
lipopolysaccharide (LPS) have been shown to increase 
global H3K9 acetylation in GECs and the gingival tissue 
in murine periodontitis [36]. However, HDAC expression 
was not evaluated in this study, and elevated H3K9 acety-
lation was attributed to activation of the HAT p300/CBP 
[36].
It is well established that dynamic regulation of activat-
ing and repressive histone methylation marks is essential 
for coordination of macrophage responses to LPS [37]. 
Accumulating evidence indicates that oral pathogens can 
induce rapid changes in histone methylation also in other 
cell types. LPS stimulation of PDL cells leads to the accu-
mulation of the activating H3K4Me3 marks and reduc-
tion of repressive H3K27 trimethylation on inflammatory 
gene promoters [38, 39]. Histone demethylase JMJD3 
(KDM6B), which catalyzes H3K27 demethylation, is 
recruited to IL6 and IL12B promoters and promotes gene 
transcription [38]. Similarly, the H3K4 methyltransferase 
SETD1B is upregulated in LPS-stimulated PDL cells and 
accumulates on the promoters of IL6 and IL1B genes 
[39]. Dynamic regulation of H3K27 as well as H3K4 tri-
methylation marks at the promoters of matrix-related 
and osteogenic genes (COL1A1, COL3A1, and RUNX2) 
and other inflammatory mediators (CCL5, IL1B) have 
also been observed in PDL cells following LPS stimula-
tion [40]. These changes favor a transcriptional program 
that suppresses PDL osteogenic differentiation [40]. In 
line with observations in isolated cell populations, unique 
histone methylation signatures have been observed in 
experimental periodontitis in mice [41]. Among them, 
the repressive H3K27Me3 mark appears to be most 
dynamically regulated under inflammatory conditions. 
H3K27 trimethylation is enriched on the promoters of 
genes involved in extracellular matrix (ECM) turnover 
and reduced on cytokine, chemokine, and defensin gene 
promoters in samples from periodontitis-affected mice 
[41]. However, changes in histone methylation marks 
on the promoters of genes regulating early signaling 
events that are critical for Toll-like receptor (TLR)- and 
cytokine-induced responses have not been evaluated in 
the context of periodontal inflammation.
Modulation of chromatin‑modifying enzymes by bacterial 
metabolic products
In periodontitis, anaerobic bacteria modulate HDAC 
function also indirectly through their fermentation prod-
ucts, such as short-chain fatty acids (SCFAs), some of 
which display HDAC inhibitory activity. Among them, 
butyric acid and propionic acid are present in the gingival 
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crevices of patients with severe periodontitis at millimo-
lar concentrations that correlate with inflammatory and 
clinical parameters of disease activity [42, 43]. To date, 
the potential pathogenic consequences of the HDACi 
activity of SCFAs produced by oral bacteria have only 
been studied in the context of viral infections. SCFAs 
produced by P. gingivalis induce reactivation of latent 
viruses, including Epstein-Barr virus [44, 45] and Kaposi’s 
Sarcoma-associated herpesvirus [46], through stimula-
tion of lytic replication. This process is associated with 
increased H4K12 acetylation, which promotes transacti-
vation of the viral chromatin [46], suggesting that manip-
ulation of HDAC activity by SCFAs may be responsible 
for the clinical progression of viral infections. Interest-
ingly, SCFA effects on host epigenetic mechanisms may 
be broader than HDAC inhibition as they have also been 
shown to decrease repressive histone trimethylation 
marks H3K27Me3 and H3K9Me3 by downregulating his-
tone methyltransferases EZH2 and SUV39H1 [46].
SCFAs released by oral pathogens may contribute 
to the pathogenesis of periodontitis also through their 
effects on structural cells of the gingival tissue. Butyric 
acid inhibits proliferation and/or induces apoptosis of 
GECs and fibroblasts in  vitro [47, 48]. High concentra-
tions of butyric acid also modulate the RANKL/OPG 
ratio in osteoblasts, favoring bone resorption, though this 
in vitro effect is highly dependent on SCFA concentration 
and time of cell exposure [49]. In contrast, a recent study 
demonstrated that SCFAs protect against inflammation-
mediated bone loss by suppressing osteoclast differen-
tiation without affecting bone formation [50]. Additional 
studies are therefore needed to fully characterize the role 
of butyric acid, and other bacterial metabolites, in bone 
homeostasis in periodontitis.
Suppression of inflammation by small molecule inhibitors 
of chromatin‑modifying enzymes
It is now well established that small molecule inhibitors 
of chromatin-modifying enzymes may affect cellular pro-
cesses that are dysregulated in pathologies associated 
with aberrant activation of the immune system, disrup-
tion of connective tissue homeostasis, and uncontrolled 
bone resorption [9, 51]. Among them, HDACi have 
received much interest due to their anti-inflammatory 
and anti-osteoclastogenic properties [52]. We have 
recently demonstrated that treatment of gingival fibro-
blasts with the pan-HDACi suberoylanilide hydroxamic 
acid (SAHA) and ITF2357 (givinostat) can suppress P. 
gingivalis-induced expression of a broad range of inflam-
matory mediators involved in periodontitis pathogen-
esis, including chemokines (CCL2, CCL5, and CXCL10), 
matrix metalloproteinases (MMP1, MMP3), and compo-
nents of the prostaglandin E2 synthesis pathway (PTGS2) 
[53]. HDACi exert similar anti-inflammatory effects on 
cells infected with F. nucleatum or stimulated with TNF 
without affecting gingival fibroblast viability or suscep-
tibility to bacterial invasion [53]. Application of a panel 
of HDACi with distinct selectivity profiles revealed that 
HDAC3 inhibition is sufficient for suppression of inflam-
matory genes in gingival fibroblasts [53]. These findings 
are consistent with previous observations in synovial 
fibroblasts [54] and macrophages [55]. Similarly, in PDL 
cells, HDACi suppress LPS-induced TNF and IL-1β 
expression and production of reactive oxygen species 
[56], and T. denticola-induced MMP2 activation [29].
In PDL cells, treatment with HDACi not only reduces 
inflammatory activation but also results in upregula-
tion of osteoblast markers, elevated levels of the tran-
scription factor RUNX2, increased alkaline phosphatase 
activity, and deposition of mineralized nodules, which 
are hallmarks of osteogenic differentiation [56, 57], rais-
ing the possibility that these compounds may facilitate 
alveolar bone regeneration. Interestingly, HDAC expres-
sion profiling in the course of PDL cell differentiation 
into osteoblasts revealed significant downregulation of 
HDAC3, and this process was accelerated by HDACi [57]. 
Together, these findings provide initial evidence suggest-
ing that inhibition of HDAC activity, in particular selec-
tive targeting of HDAC3, may be clinically beneficial in 
suppressing inflammation and promoting tissue regener-
ation in periodontitis (Table 1). HDACs may thus repre-
sent a new class of targets for host modulation therapies.
Although comprehensive analyses of changes in GEC 
activation upon treatment with HDACi are lacking, an 
initial study demonstrated that these compounds might 
enhance expression of IL8, CCL20, and hBD2 in GECs 
infected with P. gingivalis or F. nucleatum [35]. Because 
of their antimicrobial activity, induction of human 
β-defensin-2 (hBD2) and CCL20 by HDACi has been 
proposed to promote innate immune responses against 
oral pathogens. This finding is not surprising, given the 
well-documented ability of these compounds to induce 
antimicrobial peptides in epithelial cells from different 
tissues [58]. It should be noted, however, that individual 
P. gingivalis strains are resistant to hBD2 bactericidal 
activity [59], and direct antimicrobial activity of CCL20 
against oral pathogens has not yet been demonstrated. 
Collectively, these findings highlight the importance of 
HDAC activity in regulating immune responses at the 
cellular level, but more comprehensive studies are needed 
to fully characterize the influences of HDAC inhibitors 
on global inflammatory mediator output by periodontal 
tissues. However, experiments on human gingival tissue 
explants are challenging due to the scarcity of material. 
Because of that, the recently developed organotypic 3D 
models comprised of GECs and gingival fibroblasts [60], 
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which mimic many features of the native gingiva, may 
prove useful for this purpose.
To date, experimental effort has focused primarily on 
targeting HDAC activity in gingival cells, but a small 
number of recent studies have analyzed other aspects 
of chromatin-based epigenetic mechanisms that can be 
targeted with small molecule inhibitors. The discovery 
of acetylated histone mimetics that block the interaction 
between bromodomain-containing BET proteins and 
acetylated lysine residues on histone proteins has opened 
a new area for studies of the role of protein acetylation 
in human diseases [61]. These compounds have been 
highly effective in suppressing inflammation in myeloid 
cells [62], synovial fibroblasts [63], and in  vivo models 
of inflammatory diseases [62, 64]. In our recent study, 
we have shown that inflammatory gene expression is 
suppressed by the BET inhibitors I-BET151 and JQ1 in 
gingival fibroblasts and the GEC line TIGK (telomerase-
immortalized gingival keratinocyte) [65]. BET inhibitors 
reduce gingival cell activation induced by P. gingivalis 
and inflammatory cytokines and, importantly, are equally 
effective in suppressing the expression of inflamma-
tory mediators in GFs derived from healthy donors and 
periodontitis patients [65]. The cluster of mediators sus-
ceptible to inhibition by I-BET151 and JQ1 in gingival 
fibroblasts and GECs includes IL-6, IL-1β, and CCL2 
[65], elevated levels of which are most commonly found 
in patients with periodontitis [66]. This highlights the 
potential of BET inhibitors to attenuate crucial mediators 
of periodontal inflammation.
Although the key roles of histone methylation, in par-
ticular H3K4Me3 and H3K27Me3 marks, have been char-
acterized in cellular and animal models of periodontitis 
[41], the therapeutic potential of compounds that modu-
late this process has not been evaluated. Gene silencing 
studies demonstrated that manipulation of enzymes that 
regulate histone methylation can suppress inflammatory 
activation and modulate the ability of PDL cells to differ-
entiate into osteoblasts. The silencing of JMJD3 reduces 
LPS-induced IL-6, IL-8 and IL-12 production [38] and 
results in diminished alkaline phosphatase activity, 
indicative of reduced osteogenic potential [40]. SETD1B 
knockdown results in reduced IL6 and IL1B expression, 
associated with lower H3K4Me3 levels at IL6 and IL1B 
promoters [39]. It remains to be tested if pharmacological 
modulation of histone methylation regulators can reca-
pitulate the effects of gene silencing and suppress patho-
logical inflammatory processes in periodontitis. Of note, 
the selective JMJD3 inhibitor GSK-J1 displays strong 
anti-inflammatory activity in macrophages [67].
Targeting histone PTMs in experimental periodontitis
In vivo, targeting histone acetylation with HDACi or 
acetylated histone mimetics protects from alveolar bone 
loss in experimental periodontitis in rodents [68–70] 
(Table  1). The therapeutic effects of HDACi in P. gingi-
valis-induced periodontitis in mice are dependent on 
their selectivity: 1179.4b, which targets both class I and 
class II HDACs, was more potent in suppressing bone 
destruction than the class I-selective MS-275 (which 
preferentially targets HDAC1) [69]. Intriguingly, preven-
tion of bone loss in HDACi-treated animals was not asso-
ciated with reduced immune cell infiltration [69]. These 
findings indicate that, at least in this model, the ame-
lioration of disease severity by HDACi was unrelated to 
inflammation. In light of the well-documented ability of 
Table 1 Effects of small‑molecule inhibitors of epigenetic regulators in cellular and animal models of periodontitis
Epigenetic target Compound(s) Effect
HDACs SAHA, ITF2357 Suppression of P. gingivalis- and cytokine-induced CCL2, CCL5, CXCL10, MMP1, MMP3 and PTGS expres-
sion in gingival fibroblasts [53]
TSA, butyrate Upregulation of hBD2, IL-8 and CCL20 in GECs infected with P. gingivalis or F. nucleatum [35]
butyrate Suppression of LPS-induced TNF and IL-1β expression and ROS production in PDL cells [56]
TSA, apicidin Suppression of T. denticola-induced MMP2 activation in PDL cells [29]
TSA, butyrate Upregulation of osteoblast markers and induction of osteogenic differentiation of PDL cells [56, 57]
1179.4b Reduction of alveolar bone destruction in experimental periodontitis in mice [69]
TSA Reduction of inflammation and increased alveolar bone volume in experimental periodontitis in rats [68]
BET proteins I-BET151, JQ1 Suppression of inflammatory mediator production by GECs and gingival fibroblasts [65]
JQ1 Amelioration of inflammation and alveolar bone resorption in experimental periodontitis in mice [70]
DNMTs AZA Induction of differentiation of gingival fibroblasts into osteoblasts and induction of ectopic bone forma-
tion in mice [120]
Suppression of T. denticola-induced MMP2 activation in PDL cells [29]
AZA, decitabine Modulation of inflammatory cytokine production by GECs [121]
RG108 Prevention of P. gingivalis-mediated impairment of GEC barrier function [114]
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HDACi to suppress osteoclastogenesis [71], and recent 
evidence that these compounds induce osteogenic dif-
ferentiation of PDL cells [56, 57], the protective effect of 
1179.4b may be attributed to the influence of HDACi on 
alveolar bone regeneration. Indeed, the bone-protective 
effects of TSA in ligature-induced periodontitis in rats 
were associated with the ability of HDACi to induce oste-
ogenic differentiation of mesenchymal stem cells [68], 
though this effect has not been formally demonstrated 
in vivo.
The observation that HDACi failed to affect inflam-
mation in a murine periodontitis model [69] is surpris-
ing and requires independent verification using HDACi 
with well-characterized pharmacokinetic properties 
and focusing on immune and microbiological disease 
parameters. In contrast, treatment of mice with the 
BET inhibitor JQ1 reduced both alveolar bone resorp-
tion and inflammatory cytokine expression in experi-
mental periodontitis [70]. The protective effects of JQ1 
were associated with suppressed osteoclast formation 
[70], consistent with observations in other bone-related 
pathologies [72]. These results suggest that HDACs and 
BET proteins may represent attractive targets for host 
modulation therapy due to their roles in bone resorp-
tion. However, it should be noted that increased suscep-
tibility to some bacterial infections has been reported in 
mice treated with HDACi [73] and BET inhibitors [74]. 
Therefore, it will be particularly important to determine 
the influence of these compounds on pathological plaque 
formation and bacterial clearance in animal models of 
periodontitis.
DNA methylation in periodontitis
Clinical observations: aberrant DNA methylation 
in samples from periodontitis patients
DNA methylation profiles of selected gene promot-
ers have been investigated in genetic material extracted 
from human gingival biopsies in numerous studies. The 
alterations in the promoter methylation status of genes 
coding for proteins associated with inflammatory tissue 
responses and for receptors, signaling molecules, and 
transcription factors that have been observed in patients 
with periodontitis are summarized in Table 2. It is impor-
tant to note the discrepancies between the reports: in the 
case of IFNG, IL6, IL8, TNF, and TLR2, the differences in 
promoter methylation between patients with periodonti-
tis and healthy individuals observed in some studies have 
not been reproduced in independent analyses [75–86]. 
Among gene promoters analyzed in more than one study, 
the results were consistent only in the case of PTGS2 
[77, 84, 85] and STAT5A [78, 87], showing increased and 
decreased methylation in periodontitis patients, respec-
tively. A microarray-based, high-throughput analysis of 
DNA methylation in healthy donors and patients with 
periodontitis demonstrated higher variation of changes 
in genes related to immune responses, and more frequent 
decreases in their promoter methylation, though specific 
genes or gene clusters have not been reported [88]. In 
patients with aggressive periodontitis, reduced levels of 
DNA methylation in the promoters of CCL25 and IL17C 
compared to healthy controls have been identified [89]. 
Curiously, in many genes that are differentially methyl-
ated in chronic periodontitis, similar changes in DNA 
methylation have not been observed in aggressive disease 
(Table 2).
Alterations in the DNA methylation profiles in peri-
odontitis are not restricted to the site of inflammation. 
Changes in gene promoter methylation status have also 
been shown in blood samples (Table 3). Increased meth-
ylation of the TNF promoter region [90] and decreased 
IL6 promoter methylation [91] have been observed in 
the peripheral blood from patients with periodontitis, 
though the latter observation has not been confirmed in 
an independent study [79]. The levels of IL6 promoter 
methylation in the blood are significantly higher in com-
parison to the gingival tissue [79], and similar differences 
in global 5hmC levels between tissue and blood have 
been observed [92]. Moreover, epigenome-wide associa-
tion scans (EWAS) performed on blood samples in a twin 
study identified a number of differentially methylated 
genes related to self-reported periodontal traits: gingi-
val bleeding and tooth motility [93]. Eight of these genes, 
including CXCL1, IL1B, IL6ST, and CD44, were consist-
ently differentially methylated in participants with perio-
dontitis-related traits [93].
Changes in site-specific DNA methylation have also 
been  reported in the buccal mucosa from patients with 
periodontitis (Table  3). Lower methylation levels of the 
IL8 promoter region have been observed in buccal epi-
thelial cells from periodontitis patients compared to 
healthy controls, though they were not accompanied by 
similar differences in gingival biopsies [81]. A decrease in 
IL8 promoter methylation has also been shown in buccal 
epithelial cells from patients with aggressive periodontitis 
[94], whereas methylation levels of the SOCS1 promoter 
and the long interspersed nucleotide elements (LINE1 
elements) have been elevated [95]. LINE1 elements are 
repetitive DNA sequences known to undergo heavy 
methylation. Because of that, they are commonly used 
as a surrogate marker for global DNA methylation.[96]. 
Interestingly, a similar profile of associations between 
DNA methylation and periodontal traits across blood 
and the buccal tissue has been observed for a small num-
ber of genes in the EWAS study [93]. Since the micro-
biome of the buccal mucosa is altered in patients with 
periodontal disease [97] and the tissue is easily accessible, 
Page 8 of 18Jurdziński et al. Clin Epigenet          (2020) 12:186 
Table 2 Alterations in promoter methylation of selected genes in the gingival tissue from patients with periodontitis
Gene promoter Study authors Number of participants (healthy individuals: 
patients with periodontitis)
Outcome
Genes associated with tissue responses
 IFNG Zhang et al. [75] 23:12 (+ 12 participants with experimentally 
induced gingivitis)
↓ (no difference between experimentally induced 
gingivitis and healthy subjects)
Viana et al. [76] 16:18 ─
Asa’ad et al. [77] 10:10 (methylation was also assessed 2 and 
8 weeks post-therapy)
─ (no change in the course of periodontal therapy)
 IL6 Barros and Offenbacher [78] 10:10 ↑
Kobayashi et al. [79] 30:30 ─
Stefani et al. [80] 21:21 ─
 IL10 Viana et al. [76] 16:18 ─
 IL17 Barros and Offenbacher [78] 10:10 ↑
 IL17C Schulz et al. [89] 10:15 (aggressive periodontitis patients) ↓
 CXCL3 Barros and Offenbacher [78] 10:10 ↑
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
 CXCL5 Barros and Offenbacher [78] 10:10 ↑
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
 IL8 Barros and Offenbacher [78] 10:10 ↓
Oliveira et al. [81] 41:70 (periodontitis group divided into 30 smok-
ers and 40 non-smokers)
─ (no difference between smokers and non-
smokers)
 CXCL10 Barros and Offenbacher [78] 10:10 ↑
 CCL25 Schulz et al. [89] 10:15 (aggressive periodontitis patients) ↓
 TNF Zhang et al. [82] 17:18 (+ 11 participants with experimentally 
induced gingivitis)
↑ (no difference between experimentally induced 
gingivitis and healthy subjects)
Asa’ad et al. [77] 10:10 (methylation was also assessed 2- and 
8-weeks after therapy)
─ (no change in the course of periodontal therapy)
 PTGS2 (COX2) Zhang et al. [84] 6:10 ↑
Loo et al. [85] 108:110 (comparison between blood samples 
from healthy donors and gingival tissue biop-
sies from patients with periodontitis)
↑
Asa’ad et al. [77]; 10:10 (methylation was also assessed 2- and 
8-weeks after therapy)
↑ (periodontal treatment reduced the methylation 
status to the levels observed in healthy subjects)
Genes coding for receptors, signaling molecules and transcription factors of inflammation-related pathways
 TLR2 de Faria Amormino et al. [86] 20:20 ↑
De Oliveira et al. [83]; 11:23 (periodontitis group was divided into 11 
smokers and 12 non-smokers)
─ (inconclusive results: mosaic of methylated and 
unmethylated DNA. Site-specific (restriction 
enzyme-specific) trend toward increased meth-
ylation in periodontitis non-smokers)
Barros and Offenbacher [78] 10:10 ─ (strong trend toward decreased methylation in 
patients with periodontitis, which did not reach 
statistical significance)
 TLR4 De Oliveira et al. [83]; 11:23 (periodontitis group was divided into 11 
smokers and 12 non-smokers)
─ (no difference between smokers and non-
smokers)
 IL4R Barros and Offenbacher [78] 10:10 ↓
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
 IL6ST Barros and Offenbacher [78] 10:10 ↑
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
 TNFRSF18 Barros and Offenbacher [78] 10:10 ↑
 STAT5A Barros and Offenbacher [78] 10:10 ↓
Azevedo et al. [87] 20:20 ↓
 TYK2 Barros and Offenbacher [78] 10:10 ─
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
 SOCS1 Planello et al. [146] 44:46 ↓
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understanding epigenetic changes within this site could 
potentially be useful for diagnostic purposes.
In addition to gene-specific methylation studies, 
expression of DNA methyltransferases and demethylat-
ing enzymes, as well as global DNA methylation levels 
have been assessed in gingival tissues. Similar transcript 
levels of DNMT1 and DNMT3a are expressed in gingival 
biopsies from periodontitis patients and healthy controls 
[98]. Consistently, Larsson et al. found no differences in 
DNMT1 expression between periodontitis and gingivi-
tis patients. Also, there was no difference in global 5mC 
or 5hmC levels assessed by immunohistochemistry. In 
contrast, increased numbers of TET2-positive cells have 
been found in samples from periodontitis patients [92], 
though they were not associated with similar differences 
in TET2 mRNA expression in the total gingival tissue, 
suggesting that this effect may be secondary to cellu-
lar heterogeneity of the sample [92]. Collectively, these 
results indicate that alterations in the promoter-specific 
methylation profiles observed in periodontitis are not 
caused by global DNA hyper- or hypomethylation, or 
by alterations in the expression of enzymes that regulate 
this process that could be detected in total gingival tissue 
samples. Instead, they are most likely driven locally by 
exposure to bacterial factors or the inflammatory micro-
environment and are cell type-specific.
The biological relevance of the reported changes in 
DNA methylation in periodontitis is supported by studies 
of their relationship with gene expression. Negative cor-
relations between the levels of DNA methylation at gene 
promoter regions and gene expression have been found 
for TNF [82], PTGS2 [84], TLR2 [86], and IFNG [75] in 
gingival biopsies, and for IL8 in oral epithelial cells [81]. 
In blood samples, promoter methylation of TNF [90], but 
not IL6 [91], inversely correlates with serum protein lev-
els. An overall negative correlation between DNA meth-
ylation levels within gene promoters and gene expression 
in the gingival tissue has also been confirmed in a high-
throughput analysis [88]. Correlations between DNA 
methylation and gene expression, however essential, 
provide limited information about the causative relation-
ship between the two in the absence of functional stud-
ies. Furthermore, DNA methylation studies performed to 
date have predominantly focused on effector molecules, 
such as cytokines and chemokines. Although important, 
they  are not sufficient for identification of specific gene 
networks and early signaling events that are dysregu-
lated in the inflamed gingival tissue through epigenetic 
mechanisms and may represent attractive targets for 
therapeutic intervention. Thus far, few genes coding for 
receptors, signaling molecules and transcription factors 
have been analyzed in relatively small patient cohorts 
(Table  2). Well-designed high throughput epigenomic 
and transcriptomic studies are therefore needed to iden-
tify upstream signaling pathway components that are 
dysregulated in periodontitis through changes in DNA 
methylation (or other epigenetic mechanisms).
Potential relationships between clinical diagnostic 
parameters of periodontitis patients and DNA meth-
ylation of selected gene promoters have been assessed 
in two independent studies, identifying correlations of 
DNA methylation status with periodontal probing depth 
(PPD) for two promoter regions (positive correlation 
for TLR2 [86] and negative for IL-6 [79]). In contrast, 
no correlation was observed between gene methylation 
status and clinical attachment loss (CAL) as well as % 
sites with bleeding on probing (BOP) [79, 86]. De Faria 
Amormino et al. [86] have also found a positive correla-
tion between methylation of the TLR2 promoter and the 
number of inflammatory cells in the periodontal tissue 
from both healthy donors and patients with periodon-
titis. However, this correlation may be partly explained 
by differences in the cellular composition of healthy and 
inflamed tissue, especially the influx of leukocytes during 
inflammation [86]. Similarly, alterations in GATA3 meth-
ylation observed in periodontitis may simply reflect the 
accumulation of a specific lymphocyte population [78]. 
Increased numbers of inflammatory cells are associated 
The presented panel includes genes that are known to be involved in inflammatory events related to periodontitis that are divided into two groups: genes associated 
with tissue responses and genes coding for receptors, signaling molecules and transcription factors. The analyses have been conducted on genetic material isolated 
from homogenized human gingival biopsies unless otherwise indicated. The numbers of participants in both groups (healthy individuals: patients with periodontitis) 
are shown in parentheses for each study. ↓—decreased methylation in patients with periodontitis compared to healthy controls; ↑—increased methylation in 
patients with periodontitis compared to healthy controls; ─—no difference between groups
Table 2 (continued)
Gene promoter Study authors Number of participants (healthy individuals: 
patients with periodontitis)
Outcome
 SOCS3 Barros and Offenbacher [78] 10:10 ↑
 RUNX Barros and Offenbacher [78] 10:10 ↑
 GATA3 Barros and Offenbacher [78] 10:10 ↑
Schulz et al. [89] 10:15 (aggressive periodontitis patients) ─
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with spatial differences in gene expression within perio-
dontitis-affected gingival tissue [99]. Similar spatial anal-
ysis of DNA methylation combined with gene expression 
profiling could immensely contribute to a better under-
standing of the effects observed in studies of whole tissue 
samples.
Demethylation of specific CpG sites has been 
observed as a consequence of  transcription factor 
binding during inflammatory responses, leading to 
the heterogenic methylation pattern within certain 
promoters [100, 101]. The application of different 
methylation-sensitive enzymes revealed the heteroge-
neity of DNA methylation within the TLR2 promoter 
in the gingival tissue [83]. In the same study, a trend 
toward increased methylation in periodontitis patients 
has been shown for a specific CpG site, but not for 
the whole TLR2 promoter [83]. Similar heterogene-
ity of DNA methylation within individual promoters 
Table 3 Alterations in  promoter methylation of  selected genes in  the  blood and  buccal mucosa from  patients 
with periodontitis
The numbers of participants in both groups (healthy individuals: patients with periodontitis) are shown in parentheses for each study. ↓—decreased methylation in 
patients with periodontitis compared to healthy controls; ↑—increased methylation in patients with periodontitis compared with healthy controls; ─—no difference 
between groups; ↕—differential methylation (effect direction not stated)




 TNF Kojima et al. [90] 30:30 (+ 30 patients with RA) ↑ (the same effect observed in RA, but in higher 
number of CpG sites)
Kobayashi et al. [79] 30:30 ─
 IL6 Ishida et al. [91] 30:30 (+ 30 patients with RA) ↓ (the same effect observed in RA)
Kobayashi et al. [79] 30:30 ─
 VDR Kurushima et al. [93] EWAS twin study, correlation with 2 different peri-
odontal traits was analyzed separately in participants 
from TwinsUK registry (83% monozygotic and 10% 
dizygotic twins)
Gingival bleeding (528 participants: 259 negative vs 
269 positive)
Tooth mobility (492 participants: 371 negative vs 121 
positive)











 IL8 Oliveira et al. [81] 41:70 (periodontitis group was divided into 30 smokers 
and 40 non-smokers)
↓ (no difference between smokers and non-smokers)
Andia et al. [94] 37:37 (aggressive periodontitis patients) ↓
 SOCS1 Baptista et al. [95] 30:30 (aggressive periodontitis patients) ↑
 VDR Kurushima et al. [93] EWAS twin study, correlation with 2 Different periodon-
tal traits were analyzed separately:
Gingival bleeding (43 participants: 18 negative vs 25 
positive; 20 monozygotic twins, 16 dizygotic twins 
and 7 singletons)
Tooth mobility (41 participants: 29 negative vs 12 posi-
tive; 20 monozygotic twins, 12 dizygotic twins and 9 
singletons)
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and site-specific differences between healthy donors 
and patients with periodontitis have been observed 
for the TNF [82] and IFNG [75] genes analyzed by 
pyrosequencing. Such changes in DNA methylation 
restricted to specific CpG sites may be biologically 
relevant because, in many cases, the methylation sta-
tus of  individual transcription factor-binding sites 
is crucial for the regulation of gene expression [102]. 
However, the application of techniques assessing only 
site-specific DNA methylation, such as bisulfite-con-
version or digestion-based PCR methods, may partly 
explain divergent results regarding promoter methyla-
tion of the same genes analyzed in independent stud-
ies [103]. Differences in patient inclusion criteria and 
technical aspects of sample collection and processing 
may also contribute to the observed discrepancies.
Finally, little is known about the impact of poten-
tial confounding factors on the reported changes in 
DNA methylation in periodontitis patients. Among 
them, the cellular heterogeneity of tissue biopsies (as 
well as whole blood samples) may be the most impor-
tant confounder affecting the outcome in cross-sec-
tional studies [104]. It is also important to note that 
changes in DNA methylation in the total gingival tis-
sue may not reflect differences in individual cell popu-
lations. Barros et  al. [78] isolated GECs from gingival 
tissue biopsies using the laser capture microdissec-
tion method and found a cluster of inflammatory 
genes with increased methylation levels in cells from 
periodontitis patients (TYK2, IL17C, IL12B, CCL25, 
CXCL14, IL4R). Comparing this cluster to the genes 
with differential methylation profiles in periodonti-
tis-affected gingival tissue from the same patients, a 
similar effect was observed only in the case of CXCL14 
[78]. Genetic variation, age, and environmental risk 
factors that contribute to periodontitis susceptibil-
ity may also influence DNA methylation independent 
of disease-related processes [104]. Smoking is one of 
the most important, preventable risk-factor for peri-
odontal disease [105], which directly influences DNA 
methylation [106]. Promoter-specific changes in DNA 
methylation in smokers and non-smokers with peri-
odontitis have been compared in two studies, finding 
little or no differences between the groups (Table  2) 
[81, 83]. Ageing-related changes in DNA methyla-
tion correlate with increased mortality in a number of 
age-dependent disorders as well as activation of pro-
inflammatory pathways [107]. These changes are also 
influenced by obesity and alcohol consumption [108], 
which are emerging risk factors for periodontitis [109, 
110], but have not been considered in the studies avail-
able to date.
Changes of DNA methylation profiles in resident cells 
of the periodontium
Analyses of DNA methylation at individual gene promot-
ers indicate that oral pathogens and inflammatory stimuli 
tend to promote gene-specific hypermethylation in gin-
gival cells. In the most comprehensive study performed 
to date, Benakanakere et  al. [111] demonstrated that 
blunted inflammatory responses to P. gingivalis observed 
in GECs from a subset of periodontitis patients are asso-
ciated with diminished TLR2 expression and increased 
methylation of the TLR2 promoter region. Consistently, 
chronic infection with P. gingivalis induces TLR2 pro-
moter hypermethylation both in GEC cultures and the 
murine gingiva [111]. Since TLR2 is a central regulator 
of immune responses to P. gingivalis and is necessary for 
the development of pathological inflammation in murine 
models of periodontitis [112, 113], DNA methylation 
may be a crucial component of a mechanism controlling 
GEC responses to this periopathogen (Fig. 2). P. gingivalis 
infection of GECs also leads to increased methylation 
and reduced expression of genes coding for the compo-
nents of the cell–cell junction complexes (CDH1, PKP2, 
and TJP1), which results in functional impairment of 
the epithelial barrier [114]. Chronic stimulation of PDL 
cells with P. gingivalis LPS promotes hypermethylation 
of several genes encoding ECM components, including 
FANK1, COL4A1-A2, COL12A1, COL15A1, LAMA5, 
LAMB1, MMP25, POMT1, and EMILIN3, that is associ-
ated with reduced expression levels of these genes [115]. 
Preliminary analyses performed on a small number of 
gingival fibroblast lines also indicate differential methyla-
tion of individual gene promoters (CD40, IL8, TNFRSF-
10C, and MMP13) upon stimulation with IL-1β or PGE2, 
with increased methylation observed at the majority of 
the analyzed CpG sites [116].
A number of studies conducted on isolated gingi-
val and periodontal cell populations have evaluated the 
expression of DNMTs and/or global changes in DNA 
methylation in response to specific factors involved in 
periodontitis pathogenesis. Decreased expression of 
DNMT1 has been observed in primary GECs after infec-
tion with P. gingivalis or F. nucleatum [35]. Similarly, 
treatment with P. gingivalis LPS leads to the downregula-
tion of DNMT1 in PDL stem cells [117] and the HaCat 
keratinocyte cell line, but not in gingival fibroblasts [98]. 
DNMT3a mRNA expression is also reduced in HaCat 
cells exposed to P. gingivalis LPS [98]. In gingival fibro-
blasts, DNMTs are also regulated by inflammatory 
mediators that play a central role in periodontitis patho-
genesis: IL-1β upregulates DNMT1 and downregulates 
DNMT3a expression, whereas exposure to PGE2 leads 
to downregulation of both DNMT1 and DNMT3a [116]. 
Interestingly, the relationship between DNMT expression 
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and global DNA methylation is not straightforward as 
increased global 5mC levels have been observed in gin-
gival fibroblasts after stimulation with either IL-1β or 
PGE2, with a stronger effect of the latter despite down-
regulation of both DNMTs [116].
Cytidine structural analogs 5-azacytidine (AZA) and 
5-aza-2′-deoxycytidine (decitabine) can be used to spe-
cifically inhibit DNMT1 [118], though they may also 
influence other targets [119]. Treatment of gingival fibro-
blasts with AZA results in increased expression of osteo-
genic lineage markers RUNX and ALP associated with 
demethylation of their promoter regions [120]. Further-
more, pretreatment with AZA before culture in the pres-
ence of bone morphogenetic protein-2 (BMP2) promotes 
differentiation of gingival fibroblasts into functional 
osteoblasts, which may represent a novel therapeutic 
strategy for bone regeneration [120]. DNMT1 inhibition 
with AZA also suppresses T. denticola-induced upregu-
lation of MMP2 and components of its activating com-
plex (MT1-MMP and TIMP-2) in PDL cells, though it 
has not been tested whether this is caused by changes 
in MMP2 promoter methylation status [29]. In GECs, 
inhibition of DNMT1 modulates production of inflam-
matory mediators induced by oral bacteria in a complex 
manner: pretreatment with AZA enhanced P. gingivalis-
induced expression of CCL20, hBD2 [35], and IL-1α, and 
suppressed induction of IL-6 and CXCL1 by P. gingivalis, 
or F. nucleatum [121]. A similar pattern of changes in 
gene expression has been observed in GECs treated with 
decitabine prior to infection with P. gingivalis but, sur-
prisingly, not with F. nucleatum [121]. However, in these 
studies, GECs were exposed to DNMT1 inhibitors for a 
short period before infection (4 h) [35, 121], which may 
be insufficient to induce DNA hypomethylation. Finally, 
a recent study demonstrated that pretreatment of GECs 
with non-nucleoside DNMT inhibitors (RG-108, EGCG, 
or curcumin) could reverse the effects of P. gingivalis on 
methylation and expression of a cluster of genes encod-
ing components of cell–cell junction complexes, as well 
as functional impairment of the gingival epithelial barrier 
[114].
Activation of gingival cells is also regulated by proteins 
involved in DNA demethylation, mainly TET enzymes. 
In gingival fibroblasts, stimulation with IL-1β or PGE2 
results in decreased transcription of the TET1 gene but 
increased 5hmC levels [116]. Elevated 5hmC levels might 
be caused by diminished TET1 expression; since the 
enzyme has higher catalytic activity toward 5mC than 
its oxidized derivatives, its diminished expression may 
be insufficient to further oxidize 5hmC, ultimately lead-
ing to accumulation of this DNA modification [122]. 
However, it should be noted that the increases in 5hmC 
levels observed in gingival fibroblasts upon stimulation 
are accompanied by simultaneous decreases in 5mC 
levels [116]. It is yet to be assessed how pro-inflamma-
tory stimulation modulates the expression of other TET 
enzymes in these cells, in particular TET2, which plays a 
substantial role in innate immune responses of myeloid 
cells [16]. Since the TET enzymes have been shown to 
protect specific CpG sites from methylation [123], down-
regulation of TET1 in gingival fibroblasts upon inflam-
matory stimulation may also partially explain DNA 
hypermethylation observed despite decreased DNMT1 
and DNMT3a expression [116]. TET1 is also involved 
Fig. 2 Model of epigenetic regulation of TLR2 expression in 
GECs. Cell responses to P. gingivalis are predominantly mediated 
by engagement of TLR2. Under physiological conditions, P. 
gingivalis-induced activation of TLR2 stimulates the production of 
inflammatory cytokines, chemokines and antimicrobial peptides 
that promote pathogen elimination by the immune system. Chronic 
exposure to P. gingivalis, through an unknown mechanism, induces 
increased TLR2 promoter methylation in GECs, which was also 
observed in cells from a subgroup of periodontitis patients [111]. 
TLR2 promoter hypermethylation is associated with reduced TLR2 
expression and diminished production of inflammatory mediators 
and antimicrobial peptides normally induced by the pathogen [111]. 
This figure was created using images from Servier Medical Art (http://
smart .servi er.com). Servier Medical Art by Servier is licensed under a 
Creative Commons Attribution 3.0 Unported License
Page 13 of 18Jurdziński et al. Clin Epigenet          (2020) 12:186  
in the differentiation of THP-1 cells into M1 mac-
rophages after co-stimulation with P. gingivalis LPS and 
IFN-γ [124]. Similarly, TET2 silencing results in reduced 
cytokine expression in dental pulp cells after LPS stimu-
lation, associated with decreased MYD88 gene promoter 
hydroxymethylation levels and diminished NF-κB sign-
aling [125]. As these observations are based on gene 
silencing approaches, it should be noted that the TET 
enzymes can also regulate immune responses through 
mechanisms independent of DNA demethylation, includ-
ing HDAC2 recruitment [126]. Moreover, studies in den-
dritic cells suggest that DNA demethylation might not 
be the cause of induced gene expression, but rather its 
downstream consequence [101].
In vivo studies of DNA methylation in periodontitis
Although animal models of periodontitis are an excellent 
tool for spatiotemporal analysis of changes observed in 
patient-derived samples, they have not been widely used 
to study DNA methylation. Immunostaining of DNMT3b 
has been recently used as a marker of de novo DNA 
methylation to analyze the relationship between local 
and systemic infection in murine periodontitis mod-
els [127]. Palioto et al. [127] demonstrated that systemic 
microbial challenge with P. gingivalis by oral gavage, 
but not local challenge induced by ligature placement, 
increases DNMT3b levels in the gingival tissue, espe-
cially on the alveolar bone surface. Interestingly, similar 
changes in DNMT3b expression have been noted in the 
gut epithelium, suggesting that systemic effects of the 
bacterial challenge may be mediated through epigenetic 
mechanisms [127]. Murine models have also been used 
to confirm or complement in  vitro studies, demonstrat-
ing increased TLR2 promoter methylation in the gin-
gival tissue of mice challenged with P. gingivalis [111] 
and induction of ectopic bone formation by the DNMT 
inhibitor AZA [120].
Early stages of periodontitis development can also 
be studied in humans in experimental gingivitis that is 
induced by restraining from oral hygiene [128]. In this 
model, IFNG mRNA expression was even higher than in 
periodontitis patients, but returned to the levels seen in 
periodontal health after resolution of inflammation [75]. 
Curiously, this increase in gene expression in individu-
als with experimental gingivitis was not accompanied by 
decreased IFNG promoter methylation, which was noted 
in patients with periodontitis assessed in parallel [75]. 
Similarly, increased TNF promoter methylation, found in 
periodontitis patients, was not observed in experimental 
gingivitis, but in this case, decreased mRNA levels were 
observed only in patients with periodontal disease [82]. 
As gingivitis, in contrast to periodontitis, is a reversible 
form of inflammation, these results could indicate that 
alterations in DNA methylation can contribute to failure 
of inflammation resolution that is an important aspect of 
periodontitis pathogenesis [129]. Notably, pathological 
changes in DNA methylation can be reversed following 
periodontal treatment. Asa’ad et  al. [77] demonstrated 
that in patients with periodontitis, the methylation status 
of the PTGS2 promoter, which was differentially meth-
ylated compared to healthy  individuals, returned to the 
levels associated with periodontal health after conven-
tional periodontal therapy (Table 2).
Epigenetic changes as potential diagnostic 
and therapeutic targets in periodontitis
In recent years, specific DNA methylation signatures in 
blood samples have been thoroughly investigated as bio-
markers of certain types of cancer, and clinical assays 
detecting them are already commercially available [130], 
paving the way for the use of DNA methylation in the 
diagnostics of disorders with underlying epigenetic 
mechanisms [131]. Alterations in DNA methylation sta-
tus have been linked to inflammation and are currently 
evaluated as potential biomarkers in multiple diseases, 
including Crohn’s disease [132] and lupus [133], and dif-
ferential DNA methylation is associated with response 
to treatment in RA [134]. In periodontitis patients, both 
promoter-specific analyses [79, 90, 91] and EWAS [93] 
have identified altered DNA methylation signatures in 
blood samples (Table 3), raising the possibility that some 
of them, upon validation in larger patient cohorts, may 
be used for diagnostic purposes. However, their relation-
ships with disease susceptibility, progression, or sever-
ity are yet to be assessed, which will be necessary before 
considering their applicability as disease biomarkers. The 
buccal mucosa is another easily accessible tissue which 
could be used for diagnostic purposes and altered DNA 
methylation patterns have been observed in buccal epi-
thelial cells from patients with chronic [81] and aggres-
sive [94, 95] forms of the disease. Since the buccal tissue 
more closely interacts with the pathological oral micro-
biota compared to peripheral blood samples [97], it 
could provide more relevant information about disease 
pathogenesis.
Identification of confounding factors that may affect 
potential epigenetic markers will be crucial for deter-
mining their applicability in diagnostic tests and proper 
control group selection. It is important to note that DNA 
methylation patterns differ between samples from gin-
gival biopsies and the buccal mucosa [81] or blood at 
the specific CpG sites [79] and globally [92]. It is cur-
rently unknown whether these discrepancies are related 
to the disease pathobiology or are secondary to differ-
ences in cellular sample composition, which are a well-
known confounder in epigenetic studies [104]. Other 
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factors known to affect DNA methylation patterns, such 
as genetic polymorphisms, age [104], and environmental 
risk factors [135] also need to considered.
The successful introduction of epigenetic drugs into 
clinical practice in oncology and the discovery of anti-
inflammatory properties of HDAC and BET inhibitors 
have highlighted the potential for targeting epigenetic 
modifications for the treatment of multiple diseases. The 
reported initial clinical efficacy of HDACi in patients 
with graft-versus-host disease [136] and systemic-onset 
juvenile idiopathic arthritis [137], in combination with an 
acceptable profile of adverse events observed in these tri-
als, have further stimulated interest in targeting histone 
acetylation in immune-mediated inflammatory diseases. 
The available in  vitro and in  vivo observations support 
the idea that targeting HDACs or BET proteins may 
be beneficial in periodontitis by suppressing excessive 
inflammation and restoring bone homeostasis (Table 1).
However, attempts to target epigenetic modifications 
in patients with periodontal disease need to proceed 
with caution. First, evidence from clinical trials in can-
cer patients indicates that broad-spectrum HDACi have 
a number of dose-limiting toxicities, including thrombo-
cytopenia, neutropenia, fatigue, and diarrhea [138]. Such 
a profile of undesirable adverse effects can be tolerated 
in patients with life-threatening cancer but will not be 
acceptable in milder conditions. It is, however, important 
to note that HDACi exert their anti-inflammatory prop-
erties at significantly lower concentrations compared to 
those required to induce apoptosis of tumor cells [139]. 
Therefore, the doses required to achieve efficacy in 
patients with inflammatory conditions will likely have a 
more favorable safety profile. Similarly, it is expected that 
targeting individual HDACs with selective HDACi will 
result in reduced toxicity while achieving anti-inflam-
matory effects similar to pan-HDACi. In  vitro studies 
indicate that HDAC3 inhibition may be sufficient to sup-
press inflammatory activation [53, 54], though HDAC3-
selective compounds have yet to enter clinical trials. 
Second, while the reduction of excessive and non-resolv-
ing inflammation is the primary goal of host modulation 
therapy, it should not impair host responses to oral and 
other pathogens [1]. The available studies have identi-
fied several pathogen- and cell type-specific effects of 
HDACi on antimicrobial responses: while HDACi-medi-
ated induction of antimicrobial peptides by epithelial 
cells could facilitate pathogen elimination, suppression 
of macrophage and dendritic cell immune responses 
may increase susceptibility to specific bacterial or fungal 
infections [140]. Similar concerns need to be addressed 
regarding the potential application of BET inhibitors in 
periodontitis. These compounds have progressed into 
clinical trials in cancer [141], but have not been evaluated 
in patients with any inflammatory conditions, and their 
effects on host–pathogen interactions remain to be 
characterized.
Comprehensive in  vivo studies analyzing long-term 
effects of HDACi or BET inhibitor treatment on host 
responses to the dysbiotic oral microflora (as well as 
other pathogens not related to the oral microbiota) are 
therefore necessary to determine the potential conse-
quences of epigenetic therapies on the oral health and 
to identify the optimal mode of drug administration. 
The available literature does not provide definitive indi-
cations whether epigenetic changes should be targeted 
systemically or locally at the site of inflammation. This 
will ultimately depend on the relative contributions of 
dysregulated epigenetic mechanisms to the pathologi-
cal activation of different cell types that drive chronic 
inflammation in periodontitis. These cell type-specific 
effects may be impossible to address in studies of patients 
with established disease and will require a well-designed 
animal model and longitudinal studies of individuals at 
risk of developing periodontitis. This approach will allow 
for understating the complex relationships between sys-
temic epigenetic changes in circulating immune cells and 
alterations that occur locally in resident cells of the peri-
odontium at different stages of disease development and 
progression.
Summary and future perspectives
Strong experimental evidence has accumulated in the last 
decade that epigenetic regulatory mechanisms are per-
turbed in periodontitis. While alterations in DNA meth-
ylation profiles of genes involved in disease pathogenesis 
may represent potential candidates for disease biomark-
ers, proteins that regulate posttranslational histone 
modifications, in particular acetylation, have emerged 
as attractive targets for novel host modulation therapies. 
However, several gaps in our understanding of epigenetic 
regulation in periodontitis need to be filled before these 
early findings could be translated into the clinical prac-
tice. Still, little is known about the stability of changes in 
epigenetic marks over time and their long-term effects 
on gingival cell responses to inflammatory and infectious 
cues. Studies of gingival fibroblasts from patients with 
periodontitis indicate that these cells maintain their acti-
vated phenotype in vitro and are more active in response 
to P. gingivalis infection [142, 143]. Though the molecular 
mechanisms underlying this imprinted activation have 
not been identified, a possibility that it is mediated by 
alterations in the epigenetic landscape should be verified 
experimentally. Supported by the discovery of epigenet-
ically-driven “innate immune memory” in macrophages 
[144], the idea that bacterial infection can induce long-
lasting effects in host cells has recently gained significant 
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interest [145]. It is thus far unknown whether this kind of 
memory exists in gingival cells exposed to oral pathogens 
and if these changes render patients more susceptible to 
alterations in the composition of oral microflora.
The rapid development of genomic, epigenomic and 
transcriptomic methods has allowed for the identifica-
tion of causal relationships between defects in epige-
netic regulation and specific pathological mechanisms 
in many diseases [10]. These approaches should be used 
in integrated basic and clinical studies to create a com-
prehensive map of epigenetic changes in periodontitis 
and identify cell types where these changes occur. Nota-
bly, in vitro studies have predominantly focused on resi-
dent cells of periodontal tissues, but little is known about 
the dysregulation of epigenetic mechanisms in immune 
cells that infiltrate the inflamed gingiva. Global analyses 
of the epigenetic landscape need to be accompanied by 
functional studies delineating the detailed roles of indi-
vidual epigenetic enzymes in periodontitis development 
and progression. These studies are necessary to fully 
comprehend the cellular processes underlying epige-
netic alterations observed in patients with periodontitis, 
their pathophysiological consequences as well as specific 
environmental factors influencing them. Future research 
should also improve our understanding of the molecular 
mechanisms responsible for the anti-inflammatory and 
bone-protective effects of epigenetic drugs observed in 
cellular and animal models of periodontitis. The inte-
gration of experimental evidence from high-throughput 
epigenomic and functional studies will facilitate hypoth-
esis-driven decisions regarding the suitability of these 
compounds, in particular HDACi and BET inhibitors, in 
the treatment of periodontal disease.
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